Skip to main content
Top
Published in: International Urology and Nephrology 4/2012

01-08-2012 | Nephrology – Original Paper

Severity of nephrotic IgA nephropathy according to the Oxford classification

Authors: Takahito Moriyama, Kayu Nakayama, Chihiro Iwasaki, Ayami Ochi, Yuki Tsuruta, Mitsuyo Itabashi, Misao Tsukada, Takashi Takei, Keiko Uchida, Kosaku Nitta

Published in: International Urology and Nephrology | Issue 4/2012

Login to get access

Abstract

Background

IgA nephropathy with nephrotic syndrome (nephrotic IgAN) is a rare form of IgAN. Its prognosis and response to steroid therapy are still controversial because the differential diagnosis between nephrotic IgAN and minimal change nephrotic syndrome with IgA depositions is sometimes confused.

Methods

In this retrospective cohort analysis, we accurately diagnosed 42 cases of nephrotic IgAN (4.4%) from 954 IgAN patients, according to the Oxford classification. We analyzed the clinical and histological data, prognosis, and response to steroid therapy.

Results

In nephrotic IgAN, mean estimated glomerular filtration rate (eGFR) was 51.1 ± 24.6 ml/min, proteinuria was 5.71 ± 2.56 g/day, and urinary red blood cells were 51.0 ± 37.8 high power field. Both active and chronic histological lesions were observed. Cumulative renal survival rate was significantly lower in nephrotic IgAN than in non-nephrotic IgAN (the control group consisted of 47 non-nephrotic IgAN patients diagnosed between 1995 and 1996) (log-rank test: P < 0.0001). The cases with steroid therapy significantly improved their prognosis, though their male-to-female ratio and blood pressure level measured at renal biopsy were significantly lower than in the cases without steroid therapy. Steroid therapy was particularly effective in cases with low-grade tubular atrophy and interstitial fibrosis (T-grade in Oxford classification). Without steroid therapy, lower eGFR and higher T-grade were independent risk factors for severe outcome by multivariate Cox regression.

Conclusion

Nephrotic IgAN is a very severe form of IgAN, with renal dysfunction, massive hematuria, and active and chronic histopathological lesions. Renal outcome is severe; however, steroid therapy can improve prognosis in cases with higher eGFR and lower T-grade, according to the Oxford classification.
Literature
1.
go back to reference Liu XW, Li DM, Xu GS, Sun SR (2010) Comparison of therapeutic effects of leflunomide and mycophenolatemofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmacol Ther 48:509–513PubMed Liu XW, Li DM, Xu GS, Sun SR (2010) Comparison of therapeutic effects of leflunomide and mycophenolatemofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmacol Ther 48:509–513PubMed
2.
go back to reference Han SH, Kang EW, Park JK, Kie JH, Han DS, Kang SW (2010) Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy. Nephrol Dial Transpl (in press) Han SH, Kang EW, Park JK, Kie JH, Han DS, Kang SW (2010) Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy. Nephrol Dial Transpl (in press)
3.
go back to reference Kim SM, Moon KC, Oh SH et al (2009) Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J Korean Med Sci 24:S44–S49PubMedCrossRef Kim SM, Moon KC, Oh SH et al (2009) Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J Korean Med Sci 24:S44–S49PubMedCrossRef
4.
go back to reference Rašıć S, Unčanin S, Aganovıč K, Rašıć I, Džemıdžı J, Muslımovıć A (2008) Treatment of IgA nephropathy of adults presented by nephrotic syndrome. Bosn J Basic Med Sci 8:230–233PubMed Rašıć S, Unčanin S, Aganovıč K, Rašıć I, Džemıdžı J, Muslımovıć A (2008) Treatment of IgA nephropathy of adults presented by nephrotic syndrome. Bosn J Basic Med Sci 8:230–233PubMed
5.
go back to reference Maksić D, Marić M, Dimitrijević J et al (1998) Treatment of IgA nephropathy with nephrotic syndrome using pulse doses of IgG. Vojnosanit Pregl 55:79–84PubMed Maksić D, Marić M, Dimitrijević J et al (1998) Treatment of IgA nephropathy with nephrotic syndrome using pulse doses of IgG. Vojnosanit Pregl 55:79–84PubMed
6.
go back to reference Fukushi K, Yamabe H, Ozawa K et al (1988) Clinico-pathological evaluation of IgA nephropathy associated with nephrotic syndrome. Jpn J Nephrol 30:247–251 Fukushi K, Yamabe H, Ozawa K et al (1988) Clinico-pathological evaluation of IgA nephropathy associated with nephrotic syndrome. Jpn J Nephrol 30:247–251
7.
go back to reference Lai KN, Kai FM, Ho CP, Chan W (1986) Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 26:174–180PubMed Lai KN, Kai FM, Ho CP, Chan W (1986) Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 26:174–180PubMed
8.
go back to reference Lai KN, Ho CP, Chan KW, Yan KW, Lai FM, Vallance-Owen J (1985) Nephrotic range proteinuria-A good predictive index of disease in IgA nephropathy? Q J Med 57:677–678PubMed Lai KN, Ho CP, Chan KW, Yan KW, Lai FM, Vallance-Owen J (1985) Nephrotic range proteinuria-A good predictive index of disease in IgA nephropathy? Q J Med 57:677–678PubMed
9.
go back to reference Mustonen J, Pasternack P, Rantala I (1983) The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20:172–176PubMed Mustonen J, Pasternack P, Rantala I (1983) The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20:172–176PubMed
10.
go back to reference Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 53:2286–2295CrossRef Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 53:2286–2295CrossRef
11.
go back to reference Hwang HS, Kim BS, Shin YS et al (2010) Predictors for progression in immunoglobulin A nephropathy with significant proteinuria. Nephrology 15:236–241PubMedCrossRef Hwang HS, Kim BS, Shin YS et al (2010) Predictors for progression in immunoglobulin A nephropathy with significant proteinuria. Nephrology 15:236–241PubMedCrossRef
12.
go back to reference Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM (2002) Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transpl 17:1197–1203CrossRef Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM (2002) Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transpl 17:1197–1203CrossRef
13.
go back to reference A working group of the international IgA nephropathy network, the renal pathology society (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRef A working group of the international IgA nephropathy network, the renal pathology society (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRef
14.
go back to reference A working group of the international IgA nephropathy network, the renal pathology society (2009) The oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556CrossRef A working group of the international IgA nephropathy network, the renal pathology society (2009) The oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556CrossRef
15.
go back to reference Tsukada M, Honda K, Nitta K, Yumura W, Nihei H (2003) Incidental mesangial IgA deposition in minimal change nephrotic syndromes (MCNS). Jpn J Nephrol 45:681–688 Tsukada M, Honda K, Nitta K, Yumura W, Nihei H (2003) Incidental mesangial IgA deposition in minimal change nephrotic syndromes (MCNS). Jpn J Nephrol 45:681–688
16.
go back to reference Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Al Tieli P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163PubMedCrossRef Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Al Tieli P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163PubMedCrossRef
Metadata
Title
Severity of nephrotic IgA nephropathy according to the Oxford classification
Authors
Takahito Moriyama
Kayu Nakayama
Chihiro Iwasaki
Ayami Ochi
Yuki Tsuruta
Mitsuyo Itabashi
Misao Tsukada
Takashi Takei
Keiko Uchida
Kosaku Nitta
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-011-0109-5

Other articles of this Issue 4/2012

International Urology and Nephrology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine